2-Chloro-4-(5-chloro-2-methoxyphenyl)pyridine | 1235407-28-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-Chloro-4-(5-chloro-2-methoxyphenyl)pyridine
• CAS: 1235407-28-9
• 化学式: C₁₂H₉Cl₂NO
• 分子量: 254.116
• InChiKey: MENILBNTILTGNS-UHFFFAOYSA-N

物化性质

• 沸点：
  337.6±37.0 °C(Predicted)
• 密度：
  1.297±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-甲氧基-4-(4-甲基哌嗪-1-基)苯胺 、 2-Chloro-4-(5-chloro-2-methoxyphenyl)pyridine 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 20.0h， 生成 4-(5-chloro-2-methoxyphenyl)-N-[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]pyridin-2-amine
  参考文献：
  名称：

  Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors

  摘要：

  A series of compounds based on a 4-phenyl-2-phenylaminopyridine scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase (TNIK) activity are described. These compounds were used as tools to test the importance of TNIK kinase activity in signaling and proliferation in Wnt-activated colorectal cancer cells. The results indicate that pharmacological inhibition of TNIK kinase activity has minimal effects on either Wnt/TCF4/beta-catenin-driven transcription or viability. The findings suggest that the kinase activity of TNIK may be less important to Wnt signaling than other aspects of TNIK function, such as its putative role in stabilizing the TCF4/beta-catenin transcriptional complex. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.013
• 作为产物：
  描述：

  2-氯-4-碘吡啶 、 2-(5-chloro-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 4.0h， 生成 2-Chloro-4-(5-chloro-2-methoxyphenyl)pyridine
  参考文献：
  名称：

  Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors

  摘要：

  A series of compounds based on a 4-phenyl-2-phenylaminopyridine scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase (TNIK) activity are described. These compounds were used as tools to test the importance of TNIK kinase activity in signaling and proliferation in Wnt-activated colorectal cancer cells. The results indicate that pharmacological inhibition of TNIK kinase activity has minimal effects on either Wnt/TCF4/beta-catenin-driven transcription or viability. The findings suggest that the kinase activity of TNIK may be less important to Wnt signaling than other aspects of TNIK function, such as its putative role in stabilizing the TCF4/beta-catenin transcriptional complex. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.013

文献信息

• [EN] SULFONAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS SULFONAMIDES
  申请人：PFIZER LTD

  公开号：WO2010079443A1

  公开（公告）日：2010-07-15

  The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts, solvates or tautomers therof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.

  本发明涉及公式(I)的化合物及其药用可接受的盐、溶剂合物或互变异构体，以及用于制备该化合物的过程、用于制备的中间体和含有该化合物的组合物，以及该化合物的用途，特别是用于治疗疼痛。
• SULFONAMIDE DERIVATIVES
  申请人：Beaudoin Serge

  公开号：US20100197655A1

  公开（公告）日：2010-08-05

  The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.

  本发明涉及以下公式的化合物及其药学上可接受的盐、溶剂物或互变异构体，制备这些化合物的过程中使用的中间体，以及含有这些化合物的组合物，以及这些化合物的用途，特别是用于治疗疼痛。
• Sulfonamide derivatives
  申请人：Pfizer Limited

  公开号：US08153814B2

  公开（公告）日：2012-04-10

  The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.

  本发明涉及公式化合物及其药学上可接受的盐、溶剂化合物或互变异构体，制备这些化合物的方法、用于制备中间体的中间体、含有这些化合物的组合物，以及这些化合物的用途，特别是用于治疗疼痛。
• Sulfonamide Derivatives
  申请人：Beaudoin Serge

  公开号：US20120149679A1

  公开（公告）日：2012-06-14

  The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.

  本发明涉及以下公式的化合物及其药学上可接受的盐、溶剂合物或互变异构体，制备这些化合物的过程中使用的中间体，含有这些化合物的组合物，以及这些化合物的用途，特别是用于治疗疼痛。
• US8153814B2
  申请人：——

  公开号：US8153814B2

  公开（公告）日：2012-04-10